Eli Lilly and Co
NYSE:LLY
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
570.67
960.02
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Eli Lilly and Co
Eli Lilly and Co
Intangible Assets
Eli Lilly and Co
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eli Lilly and Co
NYSE:LLY
|
Intangible Assets
$6.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Intangible Assets
$39.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Intangible Assets
$27B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
93%
|
CAGR 10-Years
32%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Intangible Assets
$61.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Intangible Assets
$17B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Intangible Assets
$1.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
Glance View
Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.
See Also
What is Eli Lilly and Co's Intangible Assets?
Intangible Assets
6.5B
USD
Based on the financial report for Sep 30, 2024, Eli Lilly and Co's Intangible Assets amounts to 6.5B USD.
What is Eli Lilly and Co's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
3%
Over the last year, the Intangible Assets growth was -4%. The average annual Intangible Assets growth rates for Eli Lilly and Co have been -6% over the past three years , and 3% over the past ten years .
You don't have any saved screeners yet
